More than a week after the FDA granted an emergency use authorization (EUA) for the use of convalescent plasma against COVID-19, an NIH advisory panel is saying that there is insufficient data to recommend either for or against the treatment.

The National Institutes of Health’s COVID-19 Treatment Guidelines Panel said in a statement released today: “There are currently no data from well-controlled, adequately powered, randomized clinical trials that demonstrate the efficacy and safety of convalescent plasma for the treatment of COVID-19.”

Get the full story on our sister site Medical Design & Outsourcing.